The results showed that compared to 79,150 T2DM patients not taking SGLT2 inhibitors, 79,150 T2DM patients on SGLT2 inhibitors were associated with a lower risk of all-cause mortality (adjusted hazard ratio [aHR] 0.547; 95% confidence interval [CI] 0.482–0.621; P = 0.0001) and NOA (aHR 0.830; 95% CI 0.751–0.916; P = 0.0002) (17). Here, SLC5A2 is linked to type 2 diabetes mellitus.